RS65199B1 - Humana monoklonska antitela na teški akutni respiratorni sindrom koronavirus 2 (sars-cov-2) - Google Patents

Humana monoklonska antitela na teški akutni respiratorni sindrom koronavirus 2 (sars-cov-2)

Info

Publication number
RS65199B1
RS65199B1 RS20240202A RSP20240202A RS65199B1 RS 65199 B1 RS65199 B1 RS 65199B1 RS 20240202 A RS20240202 A RS 20240202A RS P20240202 A RSP20240202 A RS P20240202A RS 65199 B1 RS65199 B1 RS 65199B1
Authority
RS
Serbia
Prior art keywords
antibody
amino acid
seq
acid sequence
antibody fragment
Prior art date
Application number
RS20240202A
Other languages
English (en)
Serbian (sr)
Inventor
James E Crowe Jr
Seth Zost
Robert Carnahan
Pavlo Gilchuk
Original Assignee
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vanderbilt filed Critical Univ Vanderbilt
Publication of RS65199B1 publication Critical patent/RS65199B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RS20240202A 2020-03-26 2021-03-25 Humana monoklonska antitela na teški akutni respiratorni sindrom koronavirus 2 (sars-cov-2) RS65199B1 (sr)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US202063000299P 2020-03-26 2020-03-26
US202063002896P 2020-03-31 2020-03-31
US202063003716P 2020-04-01 2020-04-01
US202063023545P 2020-05-12 2020-05-12
US202063024204P 2020-05-13 2020-05-13
US202063024248P 2020-05-13 2020-05-13
US202063027173P 2020-05-19 2020-05-19
US202063037984P 2020-06-11 2020-06-11
US202063040224P 2020-06-17 2020-06-17
US202063040246P 2020-06-17 2020-06-17
US202163142196P 2021-01-27 2021-01-27
US202163161890P 2021-03-16 2021-03-16
PCT/US2021/024215 WO2021195418A1 (en) 2020-03-26 2021-03-25 Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
EP21719462.0A EP4045533B1 (en) 2020-03-26 2021-03-25 Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)

Publications (1)

Publication Number Publication Date
RS65199B1 true RS65199B1 (sr) 2024-03-29

Family

ID=75540042

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20240202A RS65199B1 (sr) 2020-03-26 2021-03-25 Humana monoklonska antitela na teški akutni respiratorni sindrom koronavirus 2 (sars-cov-2)

Country Status (31)

Country Link
US (2) US11345741B2 (enExample)
EP (2) EP4356924A3 (enExample)
JP (1) JP7819926B2 (enExample)
KR (1) KR20220158053A (enExample)
CN (1) CN115768790A (enExample)
AU (1) AU2021242306B2 (enExample)
BR (1) BR112022018949A2 (enExample)
CA (1) CA3175110A1 (enExample)
CL (1) CL2022002594A1 (enExample)
CO (1) CO2022014820A2 (enExample)
CR (1) CR20220545A (enExample)
DK (1) DK4045533T5 (enExample)
DO (1) DOP2022000199A (enExample)
EC (1) ECSP22083269A (enExample)
ES (1) ES2973425T3 (enExample)
FI (1) FI4045533T3 (enExample)
HR (1) HRP20240182T1 (enExample)
HU (1) HUE065039T2 (enExample)
IL (1) IL296537A (enExample)
LT (1) LT4045533T (enExample)
MX (1) MX2022011892A (enExample)
PE (1) PE20230415A1 (enExample)
PH (1) PH12022552500A1 (enExample)
PL (1) PL4045533T3 (enExample)
PT (1) PT4045533T (enExample)
RS (1) RS65199B1 (enExample)
SI (1) SI4045533T1 (enExample)
SM (1) SMT202400070T1 (enExample)
TW (1) TWI896628B (enExample)
UY (1) UY39135A (enExample)
WO (1) WO2021195418A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20240182T1 (hr) 2020-03-26 2024-04-26 Vanderbilt University Ljudska monoklonska protutijela za teški akutni respiratorni sindrom koronavirusa 2 (sars-cov-2)
MX2022013499A (es) 2020-04-27 2023-01-16 Twist Bioscience Corp Bibliotecas de ácidos nucleicos variantes para coronavirus.
US11740240B2 (en) * 2020-07-20 2023-08-29 Bio-Rad Laboratories, Inc. Immunoassay for SARS-CoV-2 neutralizing antibodies and materials therefor
US20220041694A1 (en) * 2020-08-10 2022-02-10 Astrazeneca Uk Limited Sars-cov-2 antibodies for treatment and prevention of covid-19
EP4196787A1 (en) 2020-08-11 2023-06-21 Zoetis Services LLC Lateral flow device for detecting sars-cov-2 antibodies in human and animal samples
EP4228697A4 (en) 2020-10-16 2025-01-01 Invisishield Technologies Ltd. Compositions for preventing or treating viral and other microbial infections
TW202342095A (zh) * 2021-11-05 2023-11-01 英商阿斯特捷利康英國股份有限公司 用於治療和預防ｃｏｖｉｄ—１９之組成物
WO2023108936A1 (zh) * 2021-12-14 2023-06-22 杭州安旭生物科技股份有限公司 一种可结合SARS-CoV-2病毒的中和抗体及其应用
TW202342510A (zh) 2022-02-18 2023-11-01 英商Ｒｑ生物科技有限公司 抗體
WO2023201306A1 (en) 2022-04-14 2023-10-19 Invisishield Technologies Ltd. Compositions for preventing or treating influenza infections
CA3256035A1 (en) 2022-04-14 2023-10-19 Invisishield Technologies Ltd. COMPOSITIONS FOR PREVENTING OR TREATMENT OF CORONAVIRUS INFECTIONS
US20250289871A1 (en) * 2022-04-29 2025-09-18 Astrazeneca Uk Limited Sars-cov-2 antibodies and methods of using the same
CN114870061B (zh) * 2022-05-31 2024-09-24 康码（上海）生物科技有限公司 一种基于病毒阻断剂的空气喷雾剂及其用途
WO2024019110A1 (ja) * 2022-07-20 2024-01-25 国立感染症研究所長が代表する日本国 ＳＡＲＳ－ＣｏＶ－２に対する抗体
CN115925934B (zh) * 2022-07-26 2025-11-07 北京昌平实验室 一种稳定性提高的人源化单克隆抗体及其应用
CN116284270A (zh) * 2022-12-29 2023-06-23 北京吉诺卫生物科技有限公司 新型三聚体重组蛋白疫苗
CN118240073B (zh) * 2024-04-19 2026-01-30 四川大学 一种对新型冠状病毒原始株和变异株S-RBD具有pH依赖结合特性的纳米抗体改造及其潜在应用

Family Cites Families (194)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4122427A (en) 1976-06-24 1978-10-24 Herbert Karsh Motion monitor
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
JPS58188433A (ja) 1982-04-28 1983-11-02 アロカ株式会社 超音波診断装置
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
EP0216846B2 (en) 1985-04-01 1995-04-26 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5141648A (en) 1987-12-02 1992-08-25 Neorx Corporation Methods for isolating compounds using cleavable linker bound matrices
US5563250A (en) 1987-12-02 1996-10-08 Neorx Corporation Cleavable conjugates for the delivery and release of agents in native form
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5088498A (en) 1988-10-17 1992-02-18 The Board Of Regents Of The University Of Washington Ultrasonic plethysmograph
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
JPH03151944A (ja) 1989-11-08 1991-06-28 Hitachi Medical Corp パルスドプラ計測装置
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
JPH049249A (ja) 1990-04-27 1992-01-14 Kusuda:Kk 塗型剤吹き付け機
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
JPH0767451B2 (ja) 1991-12-24 1995-07-26 アロカ株式会社 超音波組織変位計測装置
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
US5638824A (en) 1993-02-25 1997-06-17 Advanced Monitors Holdings Limited Ultrasonic monitor
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
WO1995015982A2 (en) 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
DE69534347T2 (de) 1994-01-31 2006-05-24 Trustees Of Boston University, Boston Bibliotheken aus Polyklonalen Antikörpern
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5573012A (en) 1994-08-09 1996-11-12 The Regents Of The University Of California Body monitoring and imaging apparatus and method
AU4289496A (en) 1994-12-02 1996-06-19 Chiron Corporation Method of promoting an immune response with a bispecific antibody
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
WO1996040662A2 (en) 1995-06-07 1996-12-19 Cellpro, Incorporated Aminooxy-containing linker compounds and their application in conjugates
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
DE19914455B4 (de) 1999-03-30 2005-07-14 Siemens Ag Verfahren zur Bestimmung der Bewegung eines Organs oder Therapiegebiets eines Patienten sowie hierfür geeignetes System
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
US7534866B2 (en) 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
US7666400B2 (en) 2005-04-06 2010-02-23 Ibc Pharmaceuticals, Inc. PEGylation by the dock and lock (DNL) technique
US7527787B2 (en) 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
US7550143B2 (en) 2005-04-06 2009-06-23 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING A POLYPEPTIDE
ES2252261T3 (es) 2000-06-28 2006-05-16 Glycofi, Inc. Metodos para producir glicoproteinas modificadas.
CA2424977C (en) 2000-10-06 2008-03-18 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
CA2953239A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
ES2193030T3 (es) 2000-11-22 2003-11-01 Brainlab Ag Metodo para determinar el volumen de los pulmones.
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
AU2002307037B2 (en) 2001-04-02 2008-08-07 Biogen Idec Inc. Recombinant antibodies coexpressed with GnTIII
SE520605C2 (sv) 2001-06-29 2003-07-29 Flir Systems Ab Optiskt system innefattande en detektor och en bländare med decentreringsfunktion
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
NZ571596A (en) 2001-08-03 2010-11-26 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
CN101613705A (zh) 2002-03-19 2009-12-30 国际植物研究所 在植物中优化聚糖生成
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
GB2396012B (en) 2002-12-03 2006-03-15 Neorad As Respiration monitor
US8814793B2 (en) 2002-12-03 2014-08-26 Neorad As Respiration monitor
EP2248892B1 (en) 2003-01-22 2015-04-22 Roche Glycart AG Fusion constructs and use of same to produce antibodies with increased FC receptor binding affinity and effector function
US6932769B2 (en) 2003-05-28 2005-08-23 Delphi Technologies, Inc. Ultrasonic occupant detection and classification system
AR047692A1 (es) 2003-07-10 2006-02-08 Epix Medical Inc Imagenes de blancos estacionarios
WO2005060520A2 (en) 2003-11-25 2005-07-07 Dana-Farber Cancer Institute, Inc. ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF
CA2549188A1 (fr) 2003-12-02 2005-06-23 Universite Paris 7 Utilisation des proteines et des peptides codes par le genome d'une nouvelle souche de coronavirus associe au sras
WO2007001352A2 (en) 2004-08-31 2007-01-04 University Of Washington Ultrasonic technique for assessing wall vibrations in stenosed blood vessels
DE112005002577T5 (de) 2004-10-18 2007-09-20 Kabushiki Kaisha Toshiba Atmungs-Überwachungs-Gerät, Atmungs-Überwachungs-System, medizinisches Verarbeitungssystem, Atmungs-Überwachungs-Verfahren und Atmungs-Überwachungs-Programm
WO2006057911A2 (en) 2004-11-22 2006-06-01 Civco Medical Instruments Co., Inc. Real time ultrasound monitoring of the motion of internal structures during respiration for control of therapy delivery
CA2604032C (en) 2005-04-06 2017-08-22 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
BRPI0611445A2 (pt) 2005-05-09 2010-09-08 Glycart Biotechnology Ag molécula de ligação a antìgeno glicomanipulada, polinucleotìdeo, polipeptìdeo, vetor, célula hospedeira, método para produção, uso e composição farmacêutica
US20060285071A1 (en) 2005-06-21 2006-12-21 Bausch & Lomb Incorporated Femtosecond laser micromachining of a contact lens and a contact lens manufactured thereby
WO2007032329A1 (ja) 2005-09-14 2007-03-22 Matsushita Electric Industrial Co., Ltd. 位置追跡方法、位置追跡装置および超音波診断装置
JP2009526520A (ja) 2006-01-17 2009-07-23 バイオレックス セラピュティックス インク 植物中でのｎ−グリカンのヒト化及び最適化のための組成物及び方法
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
RU2009116246A (ru) 2006-09-29 2010-11-10 Конинклейке Филипс Электроникс Н.В. (Nl) Способ и устройство для ультразвукового исследования, оставляющее руки свободными
US20090048518A1 (en) 2006-12-10 2009-02-19 Cardio Art Technologies Ltd. Doppler motion sensor apparatus and method of using same
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
US8591886B2 (en) 2007-07-12 2013-11-26 Gitr, Inc. Combination therapies employing GITR binding molecules
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP3124497B1 (en) 2007-09-14 2020-04-15 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
US10398393B2 (en) 2007-10-02 2019-09-03 Stryker European Holdings I, Llc Dynamic reference method and system for interventional procedures
WO2014152463A1 (en) 2013-03-15 2014-09-25 Cyberheart, Inc. Apparatus and method for real-time tracking of tissue structures
EP2242768A4 (en) * 2008-01-17 2012-03-14 Humabs Llc CROSS-NEUTRALIZATION OF HUMAN MONOCLONAL ANTIBODIES AGAINST SARS-COV AND METHODS FOR THEIR APPLICATION
GB2476623B (en) 2008-11-06 2012-11-28 Neorad As Extravasation detection for fluid injection using dopppler ultrasound blood flow measurement
US20110286916A1 (en) 2008-11-20 2011-11-24 Jose Miguel Aste-Amezaga Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use
US8637454B2 (en) 2009-01-06 2014-01-28 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
CN104119438A (zh) 2009-01-29 2014-10-29 米迪缪尼有限公司 延长体内半衰期的人抗il-6抗体及其在治疗肿瘤、自身免疫性疾病和炎症性疾病中的应用
CN102469957B (zh) 2009-07-20 2015-09-30 皇家飞利浦电子股份有限公司 用于操作监测系统的方法
US20110121996A1 (en) 2009-11-23 2011-05-26 Delphi Technologies, Inc. Method and System for Detecting an Occupant Using Reflected Signals
PL2504364T3 (pl) 2009-11-24 2017-12-29 Medimmune Limited Ukierunkowane środki wiążące przeciwko B7-H1
US20110208060A1 (en) 2010-02-24 2011-08-25 Haase Wayne C Non-contact Biometric Monitor
JP5492606B2 (ja) 2010-03-03 2014-05-14 アズビル株式会社 演算装置、及び演算装置を備えた流量計
GB2479930B (en) 2010-04-29 2017-12-06 Respinor As Coupling an ultrasound probe to the skin
BR112012027828A2 (pt) 2010-05-03 2016-08-09 Genentech Inc composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína
KR102318383B1 (ko) 2010-07-16 2021-10-27 아디맵 엘엘씨 항체 라이브러리
ES2660013T3 (es) 2010-08-13 2018-03-20 Respiratory Motion, Inc. Dispositivos y métodos para la monitorización de la variación respiratoria mediante la medición de volúmenes respiratorios, movimiento y variabilidad
WO2012033987A2 (en) 2010-09-09 2012-03-15 Purdue Research Foundation Anti-human folate receptor beta antibodies and methods of use
ES2692268T5 (en) 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
WO2012142031A1 (en) 2011-04-12 2012-10-18 Brigham And Women's Hospital, Inc. System and method for motion tracking using unique ultrasound echo signatures
US20130030285A1 (en) 2011-07-26 2013-01-31 General Electric Company System and method for integrating multiple data sources into an x-ray image referential
MY170569A (en) 2011-08-22 2019-08-19 ResMed Pty Ltd Ultrasonic welding of fabrics for sleep apnea treatment
JP5950517B2 (ja) 2011-09-02 2016-07-13 キヤノン株式会社 被検体情報取得装置、被検体情報取得方法、及びプログラム
SG11201405226TA (en) 2012-03-08 2014-11-27 Crucell Holland Bv Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
US10011660B2 (en) 2012-04-30 2018-07-03 Medimmune, Llc Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
WO2013169338A1 (en) 2012-05-11 2013-11-14 Medimmune, Llc Ctla-4 variants
JP6096459B2 (ja) 2012-10-04 2017-03-15 東芝メディカルシステムズ株式会社 超音波診断装置
BR112015016804A2 (pt) 2013-01-17 2017-07-11 Koninklijke Philips Nv método para reduzir o efeito de movimento fisiológico nos dados de imagens capturados de uma sequência de imagens médicas de um indivíduo, e método para reduzir o efeito do movimento respiratório em dados de imagem de uma sequência de imagens no tempo de ultrassom que serão usados para produzir uma curva da intensidade em função do tempo
KR20140105103A (ko) 2013-02-21 2014-09-01 삼성전자주식회사 장기의 움직임을 추적하는 방법, 장치 및 의료 영상 시스템
CN103584847B (zh) 2013-11-06 2015-04-22 中国人民解放军第三军医大学 一种非接触磁感应心率和呼吸率同步检测方法及系统
JP2015159934A (ja) 2014-02-27 2015-09-07 セイコーエプソン株式会社 超音波計測装置及び超音波計測方法
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
CN103948401A (zh) 2014-05-20 2014-07-30 夏云 一种便携式肺功能仪器及肺功能检测方法
JO3701B1 (ar) 2014-05-23 2021-01-31 Regeneron Pharma مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
CA2959571A1 (en) 2014-09-03 2016-03-10 Medimmune Limited Stable anti-il-4r-alpha antibody formulation
JP6859259B2 (ja) 2014-11-19 2021-04-14 ジェネンテック， インコーポレイテッド ＢＡＣＥｌに対する抗体及び神経疾患免疫療法のためのその使用
US9382321B2 (en) 2014-11-26 2016-07-05 Adventis Health System/Sunbelt, Inc. Effector-deficient anti-CD32A antibodies
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
ES2818103T3 (es) 2015-01-16 2021-04-09 Juno Therapeutics Inc Anticuerpos y receptores de antígenos quiméricos específicos para ROR1
CN104840218B (zh) 2015-06-09 2018-08-10 联想(北京)有限公司 一种呼吸速率的测量方法及电子设备
EP3356415B1 (en) 2015-09-29 2024-05-01 Amgen Inc. Asgr inhibitors for reduzing cholesterol levels
BR112018006251A2 (pt) 2015-09-30 2018-10-16 Janssen Biotech Inc anticorpos antagonistas que se ligam especificamente a cd40 humano e métodos de uso
GB201519985D0 (en) 2015-11-12 2015-12-30 Respinor As Ultrasonic method and apparatus for respiration monitoring
CN108367555B (zh) 2015-12-18 2023-06-13 陶氏环球技术有限责任公司 适用于热成型应用的多层膜
CN109863174B (zh) 2016-04-29 2023-06-23 维埃拉生物股份有限公司 对FcγRIIA具有特异性的结合分子及其使用
BR112019013908A2 (pt) 2017-01-06 2020-02-04 Scholar Rock, Inc. inibidores de tgfss1 isoforma-específicos, contexto-permissivos, e seus usos
TWI761453B (zh) 2017-03-01 2022-04-21 英商梅迪繆思有限公司 抗rsv單株抗體配製物
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
WO2020061159A1 (en) 2018-09-20 2020-03-26 Vanderbilt University Human antibodies to zika virus
JP2023512684A (ja) * 2020-02-03 2023-03-28 ヴィア・バイオテクノロジー・インコーポレイテッド Ｓａｒｓ－ｃｏｖ－２に対する抗体およびそれを使用する方法
JP2023519105A (ja) 2020-02-11 2023-05-10 ヴァンダービルト ユニバーシティ 重症急性呼吸器症候群コロナウイルス２（ｓａｒｓ－ｃｏｖ－２）に対するヒトモノクローナル抗体
BR112022017048A2 (pt) 2020-02-26 2022-11-16 Vir Biotechnology Inc Anticorpos contra sars-cov-2 e métodos para usar os mesmos
MX2022011142A (es) 2020-03-09 2022-12-13 Abcellera Biologics Inc Anticuerpos anti-coronavirus y metodos de uso.
US11053304B1 (en) * 2020-03-23 2021-07-06 Centivax, Inc. Anti-SARS-Cov-2 antibodies derived from 6nb6
HRP20240182T1 (hr) 2020-03-26 2024-04-26 Vanderbilt University Ljudska monoklonska protutijela za teški akutni respiratorni sindrom koronavirusa 2 (sars-cov-2)
KR20250107297A (ko) 2020-04-02 2025-07-11 리제너론 파아마슈티컬스, 인크. 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편
WO2021203053A1 (en) 2020-04-03 2021-10-07 Vir Biotechnology, Inc. Immunotherapy targeting a conserved region in sars coronaviruses
MX2021015024A (es) 2020-04-28 2022-01-18 Univ Rockefeller Anticuerpos anti-sars-cov-2 ampliamente neutralizantes y métodos de uso de los mismos.
WO2021226560A1 (en) 2020-05-08 2021-11-11 Vir Biotechnology, Inc. Antibodies against sars-cov-2
WO2021231237A2 (en) 2020-05-11 2021-11-18 Augmenta Bioworks, Inc. Antibodies for sars-cov-2 and uses thereof
CA3178663A1 (en) 2020-05-15 2021-11-18 Alejandro Rojas One-step fast gradient method for nanoantibody generation
TW202208423A (zh) 2020-05-17 2022-03-01 英商阿斯特捷利康英國股份有限公司 Ｓａｒｓ－ｃｏｖ－２抗體及其選擇和使用方法
EP4153625A4 (en) 2020-05-20 2024-09-25 The Trustees Of Columbia University In The City Of New York STRONG NEUTRALISING ANTIBODIES AGAINST SARS-COV-2, THEIR PRODUCTION AND USE
BR112022024662A2 (pt) 2020-06-03 2023-04-04 Regeneron Pharma Métodos para tratamento ou prevenção de infecções por sars-cov-2 e covid-19 com anticorpos de glicoproteína spike anti-sars-cov-2
WO2022026475A2 (en) 2020-07-27 2022-02-03 Igm Biosciences, Inc. Multimeric coronavirus binding molecules and uses thereof
US20220041694A1 (en) 2020-08-10 2022-02-10 Astrazeneca Uk Limited Sars-cov-2 antibodies for treatment and prevention of covid-19
KR20220020228A (ko) 2020-08-11 2022-02-18 (주)셀트리온 안정한 약제학적 제제
EP4288153A1 (en) 2021-02-04 2023-12-13 RQ Biotechnology Limited Antibodies
AU2022221297A1 (en) 2021-02-09 2023-08-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies targeting the spike protein of coronaviruses
JP2024511682A (ja) 2021-03-14 2024-03-14 イコサゲン セル ファクトリー オーユー ウシ初乳由来抗体及びその使用
TW202342095A (zh) 2021-11-05 2023-11-01 英商阿斯特捷利康英國股份有限公司 用於治療和預防ｃｏｖｉｄ—１９之組成物
WO2023084055A1 (en) 2021-11-12 2023-05-19 Rq Biotechnology Limited Compositions
TW202342510A (zh) 2022-02-18 2023-11-01 英商Ｒｑ生物科技有限公司 抗體

Also Published As

Publication number Publication date
ECSP22083269A (es) 2022-11-30
JP2023518849A (ja) 2023-05-08
LT4045533T (lt) 2024-02-26
TW202200610A (zh) 2022-01-01
US11345741B2 (en) 2022-05-31
AU2021242306B2 (en) 2025-05-08
CR20220545A (es) 2023-01-09
CN115768790A (zh) 2023-03-07
PT4045533T (pt) 2024-02-14
EP4045533B1 (en) 2023-11-15
AU2021242306A1 (en) 2022-11-17
MX2022011892A (es) 2022-10-18
EP4045533A1 (en) 2022-08-24
HRP20240182T1 (hr) 2024-04-26
SI4045533T1 (sl) 2024-03-29
FI4045533T3 (fi) 2024-02-02
SMT202400070T1 (it) 2024-03-13
US12216120B2 (en) 2025-02-04
ES2973425T3 (es) 2024-06-20
US20220281958A1 (en) 2022-09-08
KR20220158053A (ko) 2022-11-29
PE20230415A1 (es) 2023-03-07
TWI896628B (zh) 2025-09-11
EP4356924A2 (en) 2024-04-24
DK4045533T5 (da) 2024-07-29
DOP2022000199A (es) 2022-11-30
EP4356924A3 (en) 2024-06-12
WO2021195418A1 (en) 2021-09-30
IL296537A (en) 2022-11-01
PH12022552500A1 (en) 2024-03-25
CA3175110A1 (en) 2021-09-30
HUE065039T2 (hu) 2024-04-28
CL2022002594A1 (es) 2023-06-02
JP7819926B2 (ja) 2026-02-25
UY39135A (es) 2021-10-29
US20210300999A1 (en) 2021-09-30
PL4045533T3 (pl) 2024-04-15
DK4045533T3 (da) 2024-02-12
BR112022018949A2 (pt) 2022-11-08
CO2022014820A2 (es) 2022-10-21

Similar Documents

Publication Publication Date Title
EP4045533B1 (en) Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
US12410241B2 (en) Human monoclonal antibodies to enterovirus D68
US20210277092A1 (en) HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
US20230122364A1 (en) HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
WO2021195385A1 (en) HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-GoV-2)
US12534512B2 (en) Human monoclonal antibodies to hantavirus and methods of use therefore
US20230065377A1 (en) Human antibodies to alphaviruses
WO2024173657A9 (en) Antibodies to human pneumoviruses and methods of use therefor
US20230181714A1 (en) Human monoclonal antibodies to venezuelan equine encephalitis virus and uses therefor
US11939370B2 (en) Pan-ebola virus neutralizing human antibodies and methods of use therefor
HK40113917A (en) Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
HK40080049A (en) Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
HK40080049B (en) Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
US20250304659A1 (en) HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 1 (SARS-CoV-1)
EA049454B1 (ru) ЧЕЛОВЕЧЕСКИЕ МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА К КОРОНАВИРУСУ ТЯЖЕЛОГО ОСТРОГО РЕСПИРАТОРНОГО СИНДРОМА 2 (SARS-CoV-2)
EP4720675A2 (en) Human monoclonal antibodies for human parainfluenza virus type 3
US20230085393A1 (en) Human antibodies that neutralize zika virus and methods of use therefor
WO2025024431A1 (en) Broadly reactive antibodies to influenza b viruses
AU2020273365A1 (en) Human antibodies to Ross River virus and methods of use therefor